PortfoliosLab logo
UTHR vs. SRPT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between UTHR and SRPT is 0.37, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

UTHR vs. SRPT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in United Therapeutics Corporation (UTHR) and Sarepta Therapeutics, Inc. (SRPT). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

UTHR:

0.62

SRPT:

-0.95

Sortino Ratio

UTHR:

0.91

SRPT:

-1.65

Omega Ratio

UTHR:

1.13

SRPT:

0.74

Calmar Ratio

UTHR:

0.54

SRPT:

-0.86

Martin Ratio

UTHR:

1.20

SRPT:

-1.86

Ulcer Index

UTHR:

14.55%

SRPT:

36.96%

Daily Std Dev

UTHR:

31.71%

SRPT:

70.23%

Max Drawdown

UTHR:

-93.18%

SRPT:

-98.17%

Current Drawdown

UTHR:

-21.86%

SRPT:

-78.40%

Fundamentals

Market Cap

UTHR:

$14.45B

SRPT:

$3.66B

EPS

UTHR:

$25.47

SRPT:

-$2.64

PEG Ratio

UTHR:

1.43

SRPT:

159.25

PS Ratio

UTHR:

4.83

SRPT:

1.64

PB Ratio

UTHR:

2.09

SRPT:

3.20

Total Revenue (TTM)

UTHR:

$2.99B

SRPT:

$2.23B

Gross Profit (TTM)

UTHR:

$2.66B

SRPT:

$1.81B

EBITDA (TTM)

UTHR:

$1.56B

SRPT:

-$117.73M

Returns By Period

In the year-to-date period, UTHR achieves a -9.20% return, which is significantly higher than SRPT's -68.25% return. Over the past 10 years, UTHR has outperformed SRPT with an annualized return of 5.81%, while SRPT has yielded a comparatively lower 4.46% annualized return.


UTHR

YTD

-9.20%

1M

6.52%

6M

-15.28%

1Y

19.67%

3Y*

10.75%

5Y*

22.12%

10Y*

5.81%

SRPT

YTD

-68.25%

1M

-36.55%

6M

-72.01%

1Y

-66.79%

3Y*

-19.73%

5Y*

-24.00%

10Y*

4.46%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


United Therapeutics Corporation

Sarepta Therapeutics, Inc.

Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

UTHR vs. SRPT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

UTHR
The Risk-Adjusted Performance Rank of UTHR is 6868
Overall Rank
The Sharpe Ratio Rank of UTHR is 7373
Sharpe Ratio Rank
The Sortino Ratio Rank of UTHR is 6262
Sortino Ratio Rank
The Omega Ratio Rank of UTHR is 6464
Omega Ratio Rank
The Calmar Ratio Rank of UTHR is 7373
Calmar Ratio Rank
The Martin Ratio Rank of UTHR is 6666
Martin Ratio Rank

SRPT
The Risk-Adjusted Performance Rank of SRPT is 33
Overall Rank
The Sharpe Ratio Rank of SRPT is 55
Sharpe Ratio Rank
The Sortino Ratio Rank of SRPT is 44
Sortino Ratio Rank
The Omega Ratio Rank of SRPT is 33
Omega Ratio Rank
The Calmar Ratio Rank of SRPT is 33
Calmar Ratio Rank
The Martin Ratio Rank of SRPT is 11
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

UTHR vs. SRPT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for United Therapeutics Corporation (UTHR) and Sarepta Therapeutics, Inc. (SRPT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current UTHR Sharpe Ratio is 0.62, which is higher than the SRPT Sharpe Ratio of -0.95. The chart below compares the historical Sharpe Ratios of UTHR and SRPT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

UTHR vs. SRPT - Dividend Comparison

Neither UTHR nor SRPT has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

UTHR vs. SRPT - Drawdown Comparison

The maximum UTHR drawdown since its inception was -93.18%, smaller than the maximum SRPT drawdown of -98.17%. Use the drawdown chart below to compare losses from any high point for UTHR and SRPT.


Loading data...

Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

UTHR vs. SRPT - Volatility Comparison

The current volatility for United Therapeutics Corporation (UTHR) is 8.07%, while Sarepta Therapeutics, Inc. (SRPT) has a volatility of 40.27%. This indicates that UTHR experiences smaller price fluctuations and is considered to be less risky than SRPT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading data...

Financials

UTHR vs. SRPT - Financials Comparison

This section allows you to compare key financial metrics between United Therapeutics Corporation and Sarepta Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


100.00M200.00M300.00M400.00M500.00M600.00M700.00M800.00M20212022202320242025
794.40M
744.86M
(UTHR) Total Revenue
(SRPT) Total Revenue
Values in USD except per share items

UTHR vs. SRPT - Profitability Comparison

The chart below illustrates the profitability comparison between United Therapeutics Corporation and Sarepta Therapeutics, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

80.0%85.0%90.0%95.0%20212022202320242025
88.4%
81.5%
(UTHR) Gross Margin
(SRPT) Gross Margin
UTHR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, United Therapeutics Corporation reported a gross profit of 701.90M and revenue of 794.40M. Therefore, the gross margin over that period was 88.4%.

SRPT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported a gross profit of 607.29M and revenue of 744.86M. Therefore, the gross margin over that period was 81.5%.

UTHR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, United Therapeutics Corporation reported an operating income of 382.80M and revenue of 794.40M, resulting in an operating margin of 48.2%.

SRPT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported an operating income of -300.39M and revenue of 744.86M, resulting in an operating margin of -40.3%.

UTHR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, United Therapeutics Corporation reported a net income of 322.20M and revenue of 794.40M, resulting in a net margin of 40.6%.

SRPT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported a net income of -447.51M and revenue of 744.86M, resulting in a net margin of -60.1%.